drugset / Trial / NCT04724343

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

NCT04724343

Phase 4 Completed 50 enrolled Damascus University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this prospective, non-randomised, open-label, clinical trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation.

Timeline

Start
2019-12-22
Primary completion
2022-01-01
Completion
2022-07-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrorelix Other / unclassified 0.25 mg Subcutaneous
Comparator Triptorelin Other / unclassified 0.05 mg Subcutaneous
Comparator Triptorelin Other / unclassified 0.1 mg Subcutaneous
Background Gonal-f Protein / enzyme biologic
Background human chorionic gonadotropin Protein / enzyme biologic 10000 iu
Background human chorionic gonadotropin Protein / enzyme biologic

Indications